Medical Policy
Phototherapy and Photochemotherapy for Dermatologic Conditions

Policy Number: 043

<table>
<thead>
<tr>
<th>Authorization required</th>
<th>Commercial and Connector/Qualified Health Plans</th>
<th>MassHealth</th>
<th>Medicare Advantage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Photochemotherapy</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>UVB Excimer Laser Therapy</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>No Prior Authorization</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Overview
The purpose of this document is to describe the guidelines Mass General Brigham Health Plan utilizes to determine medical appropriateness for phototherapy, photochemotherapy, excimer laser therapy, and photodynamic therapy. The treating specialist must request prior authorization for photochemotherapy and excimer laser therapy.

Coverage Guidelines
Mass General Brigham Health Plan covers phototherapy, photochemotherapy, excimer laser therapy, and photodynamic therapy for the treatment of certain skin conditions, or cancers, when such treatment is recommended by the member’s primary care physician or dermatologist. In addition, photochemotherapy, and excimer laser therapy must meet the medical necessity criteria indicated below.

Photodynamic therapy, UVA, UVB Phototherapy, and Narrow Band UVB Phototherapy are covered without prior authorization as reflected in the table listed above.

UVB Photochemotherapy
Mass General Brigham Health Plan covers medically necessary UVB Photochemotherapy (using petrolatum/mineral oil and generally, narrow band UVB) up to three times per week for up to three months for the following conditions characterized by thickened plaque or scale:

- Atopic dermatitis (eczema)
- Cutaneous T Cell Lymphoma (CTCL)
- Lichen planus
- Pityriasis lichenoides chronica
- Pityriasis lichenoides et varioliformis acuta (PLEVA)
- Psoriasis

When, except for CTCL, one of the following has been met:
1. Moderate to severe disease with 10% or greater body surface area involvement; or
2. In extenuating circumstances: site involvement (scalp, palms, soles); or

---

1 Only covered for specific conditions for the treatment of an actinic keratosis, a malignant neoplasm of the skin, or a carcinoma in situ of the skin. Photodynamic therapy is not a covered benefit for any other diagnosis. Photodynamic therapy does not require prior authorization when used for the treatment of covered conditions.
3. A two-week trial of at least one of the following therapies has failed:
   a. Topical or oral corticosteroids
   b. Topical calcipotriene
   c. Topical calcineurin inhibitors\(^2\)
   d. Topical tazarotene\(^1\)

Mass General Brigham Health Plan covers maintenance treatments when documentation shows that the skin condition has been treated successfully and requires continued maintenance. Up to 30 additional treatments per 12-month period. Further authorizations will be reviewed on a case by case basis.

**UVA Photochemotherapy or PUVA (the use of psoralen with UVA phototherapy)**
Mass General Brigham Health Plan covers medically necessary PUVA for new lesions up to three times per week for up to three months, for the following conditions:

- Alopecia areata
- Atopic dermatitis (eczema) after failing narrow band UVB therapy
- Cutaneous T-Cell Lymphoma (CTCL) (Mycosis fungoides stage 1 and stage 2)
- Granuloma Annulare- Generalized variant
- Lichen planus after failing narrow band UVB therapy
- Pityriasis lichenoides et varioliformis acuta (PLEVA) after failing narrow band UVB phototherapy
- Psoriasis after failing narrow band UVB therapy
- Vitiligo on the face, anterior neck and/or hands after failing narrow band UVB phototherapy
- Urticaria Pigmentosa in conjunction with cromoglycalates, antihistamines, or leukotriene modifying agents
- Parapsoriasis
- Pruritis

When, except for CTCL, one of the following has been met:

1. Moderate to severe disease with 10% or greater body surface area involvement; or
2. In extenuating circumstances: Site involvement (scalp, palms, soles); or
3. At least a two-week trial of the following therapies has failed:
   a. Topical or oral corticosteroids
   b. Topical calcipotriene
   c. Topical calcineurin inhibitors\(^1\)
   d. Topical tazarotene\(^1\)

Mass General Brigham Health Plan covers maintenance treatments when documentation shows that the skin condition has been treated successfully and requires continued maintenance. Up to 30 additional treatments per 12-month period.

**UVB Excimer Laser Therapy**
Mass General Brigham Health Plan covers medically necessary UVB excimer laser treatment for:

**A. Psoriasis** when both of the following are met:

1. The psoriatic lesions being treated cover less than or equal to 5% of the total body surface area; and
2. A two-month trial of at least two of the following therapies has failed:
   a. Topical or oral corticosteroids
   b. Topical calcipotriene

\(^2\) Medications may be subject to step therapy through the pharmacy program.
c. Topical calcineurin inhibitors

d. Topical tazarotene

Initial authorization is limited to 15 treatments, and if significant improvement is demonstrated, up to 15 additional treatments may be authorized.

B. Vitiligo when:

1. Vitiligo involves less than 5% of the member’s body surface area; OR
2. The area being treated for vitiligo cannot be adequately reached during light box therapy (e.g., treatment of the face, fingers, neck, scalp, toes, special sites); OR
3. The member requires treatment for vitiligo but has a contraindication for total body phototherapy

Treatment of vitiligo with laser therapy is limited to no more than 12 consecutive, calendar weeks with a review required for up to 12 additional treatments.

Exclusions

Mass General Brigham Health Plan does not provide coverage for photochemotherapy, UVB excimer laser treatments, or photodynamic therapy for conditions that do not meet the criteria noted above.

Medicare Variation

Mass General Brigham Health Plan uses guidance from the Centers for Medicare and Medicaid Services (CMS) for coverage determinations for its Medicare Advantage plan members. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs) and documentation included in the Medicare manuals are the basis for coverage determinations. When there is no guidance from CMS for the requested service, Mass General Brigham Health Plan’s medical policies are used for coverage determinations.

At the time of Mass General Brigham Health Plan’s most recent policy review, Medicare has an NCD for Treatment of Psoriasis (250.1). For other procedures please follow the Phototherapy and Photochemotherapy for Dermatologic Conditions medical policy.

Definitions

Excimer Laser Therapy: Treatment by emitting light of wavelength 308 nm and is thus similar to the 311 nm of the established narrow band (NB) UVB therapy.

Phototherapy: The exposure to nonionizing radiation for therapeutic benefit. It may involve exposure to ultraviolet A, wavelength 320-400 nanometers (UVA), ultraviolet B, wavelength 290-300 nanometers (UVB), narrow band UVB, wavelength 311-313 nanometers (NB UVB), or various combinations of UVA and UVB radiation.

Photochemotherapy: The therapeutic use of radiation in combination with a photosensitizing chemical. Treatment with these modalities may involve partial or whole-body exposure.

Photodynamic Therapy: Targeted therapy, which uses a light-sensitive drug that is activated inside the body by laser light to kill cells.

Related Policies

• Medicare Advantage Administration Guidelines Medical Policy

Codes

The following codes are included below for informational purposes only; inclusion of a code does not constitute or imply coverage.

The following list of codes applies to commercial and MassHealth plans only.
<table>
<thead>
<tr>
<th>Authorized CPT/HCPCS Codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>96910</td>
<td>Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B</td>
</tr>
<tr>
<td>96912</td>
<td>Photochemotherapy; psoralens and ultraviolet A (PUVA)</td>
</tr>
<tr>
<td>96913</td>
<td>Photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least 4-8 hours of care under direct supervision of the physician (includes application of medication and dressings)</td>
</tr>
<tr>
<td>96920</td>
<td>Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm</td>
</tr>
<tr>
<td>96921</td>
<td>Laser treatment for inflammatory skin disease (psoriasis); 250 sq cm to 500 sq cm</td>
</tr>
<tr>
<td>96922</td>
<td>Laser treatment for inflammatory skin disease (psoriasis); over 500 sq cm</td>
</tr>
</tbody>
</table>

Effective

February 2023: Annual Update. The following changes were made:

- Page 1. Added Medicare Advantage to table. Added Photodynamic therapy to statement regarding table.
- Page 2: Under UVA Photochemotherapy or PUVA section, added Mycosis fungoides, parapsoriasis, and pruritis. Also added “At least” to statement regarding CTCL trial.
- Page 3: Under UVB Excimer Laser treating Vitiligo, added special sites to treatment area; item B. 2. Added Medicare Variation language. Added statement regarding coding applying to commercial and MassHealth plans only.
- Page 5: References updated.

January 2022: Annual Update.


January 2020: Annual Update. Added Alopecia areata to conditions under UVA Photochemotherapy or PUVA. Added Vitiligo criteria under UVB Excimer Laser Therapy. References updated.

January 2019: Annual Update. Under UVB Excimer Laser Therapy, changed trial from 3 months to 2 months. References updated.

April 2018: Added procedure codes.

December 2017: Annual Update

July 2017: Added clarifying sentence on page 1: “UVA and UVB Phototherapy are covered without prior authorization as reflected in the table listed above.” Edited two conditions under UVA Photochemotherapy or PUVA to read after failing narrow band UVB phototherapy.

April 2017: Annual Update.

April 2016: Annual Update.

April 2015: Annual Update.

April 2014: Annual Update.

April 2013: Annual update, modified coverage conditions, and conventional therapy. Removed Vitiligo as a covered condition.

November 2011: Effective date.

References


Goldstein, & Goldstein. Pityriasis rosea. Version 18.3. Uptodate.com

Goldstein, & Goldstein. Vitiligo. Version 18.3. Uptodate.com


